ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1221 • ACR Convergence 2020

    Evaluation of Methotrexate Efficacy and Exploration of Metabolites Associated with Disease Activity in Collagen-induced Arthritis Mouse Model

    Yu Kyoung Cho1 and Ryan Funk1, 1UNIVERSITY OF KANSAS, Kansas City, KS

    Background/Purpose: Methotrexate (MTX) is cornerstone of therapy for rheumatoid arthritis. However, response to MTX is variable and unpredictable among patients. Therefore, there is a critical…
  • Abstract Number: 1227 • ACR Convergence 2020

    Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors

    Borja Hernandez-Breijo1, Chamaida Plasencia2, Victoria Navarro-Compán3, Israel Nieto-Gañán4, Cristina Sobrino5, Ana Martínez-Feito6, Carlota García-Hoz4, Paloma Lapuente-Suanzes4, Javier Bachiller-Corral7, Gema Bonilla2, Cristina Pijoán-Moratalla7, Garbiñe Roy4, Mónica Vázquez7, Alejandro Balsa2, Luisa M Villar4, Dora Pascual-Salcedo8 and Eulalia Rodríguez-Martín4, 1Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, 2Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, 3Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 4Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, 5Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, 6Hospital Unversitario La Paz- idipaz, Madrid, Spain, 7Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 8Hospital Universitario La Paz- Idipaz, Madrid, Spain

    Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to…
  • Abstract Number: 1226 • ACR Convergence 2020

    Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK

    Roxanne Cooksey1, Sinead Brophy1, Muhammad Azizur1, Jonathan Kennedy1 and Ernest Choy2, 1Swansea University, Swansea, Wales, United Kingdom, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics.  Etanercept biosimilar,…
  • Abstract Number: 1232 • ACR Convergence 2020

    Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)

    Andrea Rubbert Roth1, Daniel Furst*2, Stefano Fiore3, Amy Praestgaard4, Vivian Bykerk5, Clifton Bingham III6 and Christina Charles-Schoeman7, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 3Sanofi, Bridgewater, NJ, 4Sanofi, Cambridge, MA, 5Hospital for Special Surgery, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
  • Abstract Number: 1234 • ACR Convergence 2020

    Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab

    Ernest Choy1, Vivian Bykerk2, Yvonne Lee3, Gregory St John4, Hubert van Hoogstraten5, Kerri Ford6, Amy Praestgaard6 and Anthony Sebba7, 1CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Sanofi, Cambridge, MA, 7Arthritis Associates, Palm Harbor, Tampa, FL

    Background/Purpose: Inflammation is a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected…
  • Abstract Number: 1229 • ACR Convergence 2020

    Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis

    Eulalia Rodriguez-Martín1, Israel Nieto-Gañán1, Borja Hernández-Breijo2, Cristina Sobrino3, Carlota García-Hoz1, Javier Bachiller-Corral4, Ana Martínez-Feito5, Victoria Navarro-Compán6, Paloma Lapuente-Suanzes1, Gema Bonilla7, Dora Pascual-Salcedo8, Garbiñe Roy1, Teresa Jurado2, Pilar Nozal2, Mónica Vázquez4, Alejandro Balsa7, Luisa M Villar1 and Chamaida Plasencia7, 1Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, 2Hospital Universitario La Paz-Idipaz, Madrid, Spain, 3Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, 4Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 5Hospital Unversitario La Paz- idipaz, Madrid, Spain, 6Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 7Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 8Hospital Universitario La Paz- Idipaz, Madrid, Spain

    Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
  • Abstract Number: 1224 • ACR Convergence 2020

    Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab

    Esteban Rubio Romero1, Alejandro Muñoz Jiménez2, Rosalia Martinez Perez3 and Lara Mendez Diaz4, 1VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, 2H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 3Virgen del Rocío University Hospital, seville, Spain, 4Virgen del Rocío Hospital, sevilla, Spain

    Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
  • Abstract Number: 1237 • ACR Convergence 2020

    Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials

    Anthony Sebba1, Jian Han2 and Shalini V. Mohan2, 1Arthritis Associates, Palm Harbor, Tampa, FL, 2Genentech, South San Francisco, CA

    Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
  • Abstract Number: 1240 • ACR Convergence 2020

    An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis

    Muhammad Shipa1, Su-Ann Yeoh1, Dev Mukerjee2 and Michael Ehrenstein1, 1University College London, LONDON, United Kingdom, 2North Middlesex University hospital NHS Trust, London, United Kingdom

    Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
  • Abstract Number: 1241 • ACR Convergence 2020

    Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries

    Hugo Madariaga1, Juan Reyes2, Magda Gutierrez3, Dario Ponce de Leon4, Tatjana Lukic5 and Luisa Amador2, 1Centro Medico CEEN, Arequipa, Arequipa, Peru, 2Pfizer, Bogota, Cundinamarca, Colombia, 3Pfizer, Santiago, Region Metropolitana, Chile, 4PFIZER, LIMA, Peru, 5Pfizer Inc, New York, NY

    Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
  • Abstract Number: 1236 • ACR Convergence 2020

    Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials

    Sebastian Unizony1, Joseph Dang2, Jian Han3, Margaret Michalska2 and Jennie H. Best2, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, 3Genentech, South San Francisco, CA

    Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
  • Abstract Number: 1247 • ACR Convergence 2020

    Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort

    Achille Marino1, Micol Romano2, Teresa Giani3, Carla Gaggiano4, Stefania Costi5, Revika Singh6, Jay Mehta7, Scott Lieberman8 and Rolando Cimaz9, 1Department of Pediatrics, Desio Hospital, Milan, 2ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, 3AOU Meyer, Florence, Italy, 4Department of Pediatrics, University of Siena, Siena, Italy, Siena, Italy, 5University of Milan, Milan, Italy, Milan, Italy, 6Northwestern University, Evanston, IL, 7Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA, Philadelphia, PA, 8Department of Pediatrics, University of Iowa, Iowa City, US, Iowa City, IA, 9ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy

    Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune chronic disease characterized by inflammation of exocrine glands, but it can affect other organs as well.This study aims…
  • Abstract Number: 1244 • ACR Convergence 2020

    Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease

    Joanna Marco1, Gregory Gardner1 and Nishant Gupta2, 1University of Washington, Seattle, WA, 2University of Cincinnati, Cincinnati

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
  • Abstract Number: 1239 • ACR Convergence 2020

    Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis

    Peter Taylor1, Amer Mirza2, Bryan Downie2, Jinfeng Liu2, Rachael Hawtin2 and Emon Elboudwarej2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City

    Background/Purpose: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA),…
  • Abstract Number: 1131 • ACR Convergence 2020

    Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model

    Mithu Maheswaranathan1, Kevin McKenna2, Amy Corneli2, David Pisetsky3, Megan Clowse4 and Amanda Eudy1, 1Duke University, Durham, NC, 2Duke University, Durham, 3Duke University Medical Center, Durham, NC, 4Duke University, Chapel Hill, NC

    Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used.  We…
  • « Previous Page
  • 1
  • …
  • 707
  • 708
  • 709
  • 710
  • 711
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology